Cargando…

Trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma

BACKGROUND: Anal squamous cell carcinoma patients often present with significant symptoms, including pain, bleeding, and obstructive symptoms. This requires palliation‐directed therapy as a first‐line treatment to alleviate symptoms. The proportion of patients receiving first‐line palliative treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Radhakrishnan, Srinidhi J., Goksu, Suleyman Y., Radhakrishnan, Saikripa M., Beg, Muhammad S., Sanford, Nina N., Kazmi, Syed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939099/
https://www.ncbi.nlm.nih.gov/pubmed/36082966
http://dx.doi.org/10.1002/cam4.5126
_version_ 1784890770658951168
author Radhakrishnan, Srinidhi J.
Goksu, Suleyman Y.
Radhakrishnan, Saikripa M.
Beg, Muhammad S.
Sanford, Nina N.
Kazmi, Syed M.
author_facet Radhakrishnan, Srinidhi J.
Goksu, Suleyman Y.
Radhakrishnan, Saikripa M.
Beg, Muhammad S.
Sanford, Nina N.
Kazmi, Syed M.
author_sort Radhakrishnan, Srinidhi J.
collection PubMed
description BACKGROUND: Anal squamous cell carcinoma patients often present with significant symptoms, including pain, bleeding, and obstructive symptoms. This requires palliation‐directed therapy as a first‐line treatment to alleviate symptoms. The proportion of patients receiving first‐line palliative treatments is unknown. We aimed to study the factors associated with the use of first‐line palliative treatments in stage II–IV anal squamous cell carcinoma patients. METHODS: We used the National Cancer Database to identify adult patients diagnosed with stage II–IV anal squamous cell carcinoma between 2004 and 2016. We performed univariable and multivariable logistic regression analysis to determine the clinical and sociodemographic variables associated with the utilization of palliative treatment in the first‐line setting, including palliative radiotherapy, chemotherapy, surgery, and pain management. RESULTS: Among 16,944 patients diagnosed with stage II–IV anal squamous cell carcinoma, only a small proportion of 492 (2.9%) required first‐line palliative treatments to control symptoms. The majority of these patients received palliative radiotherapy (32%), followed by palliative surgery (25%), palliative chemotherapy (19%), combination therapies (14%), and pain management (10%). On multivariable analysis, higher stage disease, lower income, Medicare and Medicaid insurance, and life expectancy <6 months were associated with higher odds of use of first‐line palliative therapy. CONCLUSIONS: First‐line use of palliative treatments to control symptoms is needed in a small proportion of anal squamous cell cancer patients. It was utilized in all stages, but it was most frequently observed in patients with stage IV disease and patients with <6 months life expectancy. First‐line palliative therapy was also more frequent in lower‐income patients and patients with Medicare and Medicaid insurance which highlights the disparities in anal cancer management.
format Online
Article
Text
id pubmed-9939099
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99390992023-02-20 Trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma Radhakrishnan, Srinidhi J. Goksu, Suleyman Y. Radhakrishnan, Saikripa M. Beg, Muhammad S. Sanford, Nina N. Kazmi, Syed M. Cancer Med RESEARCH ARTICLES BACKGROUND: Anal squamous cell carcinoma patients often present with significant symptoms, including pain, bleeding, and obstructive symptoms. This requires palliation‐directed therapy as a first‐line treatment to alleviate symptoms. The proportion of patients receiving first‐line palliative treatments is unknown. We aimed to study the factors associated with the use of first‐line palliative treatments in stage II–IV anal squamous cell carcinoma patients. METHODS: We used the National Cancer Database to identify adult patients diagnosed with stage II–IV anal squamous cell carcinoma between 2004 and 2016. We performed univariable and multivariable logistic regression analysis to determine the clinical and sociodemographic variables associated with the utilization of palliative treatment in the first‐line setting, including palliative radiotherapy, chemotherapy, surgery, and pain management. RESULTS: Among 16,944 patients diagnosed with stage II–IV anal squamous cell carcinoma, only a small proportion of 492 (2.9%) required first‐line palliative treatments to control symptoms. The majority of these patients received palliative radiotherapy (32%), followed by palliative surgery (25%), palliative chemotherapy (19%), combination therapies (14%), and pain management (10%). On multivariable analysis, higher stage disease, lower income, Medicare and Medicaid insurance, and life expectancy <6 months were associated with higher odds of use of first‐line palliative therapy. CONCLUSIONS: First‐line use of palliative treatments to control symptoms is needed in a small proportion of anal squamous cell cancer patients. It was utilized in all stages, but it was most frequently observed in patients with stage IV disease and patients with <6 months life expectancy. First‐line palliative therapy was also more frequent in lower‐income patients and patients with Medicare and Medicaid insurance which highlights the disparities in anal cancer management. John Wiley and Sons Inc. 2022-09-09 /pmc/articles/PMC9939099/ /pubmed/36082966 http://dx.doi.org/10.1002/cam4.5126 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Radhakrishnan, Srinidhi J.
Goksu, Suleyman Y.
Radhakrishnan, Saikripa M.
Beg, Muhammad S.
Sanford, Nina N.
Kazmi, Syed M.
Trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma
title Trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma
title_full Trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma
title_fullStr Trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma
title_full_unstemmed Trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma
title_short Trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma
title_sort trends in utilization of first‐line palliative treatments for anal squamous cell carcinoma
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939099/
https://www.ncbi.nlm.nih.gov/pubmed/36082966
http://dx.doi.org/10.1002/cam4.5126
work_keys_str_mv AT radhakrishnansrinidhij trendsinutilizationoffirstlinepalliativetreatmentsforanalsquamouscellcarcinoma
AT goksusuleymany trendsinutilizationoffirstlinepalliativetreatmentsforanalsquamouscellcarcinoma
AT radhakrishnansaikripam trendsinutilizationoffirstlinepalliativetreatmentsforanalsquamouscellcarcinoma
AT begmuhammads trendsinutilizationoffirstlinepalliativetreatmentsforanalsquamouscellcarcinoma
AT sanfordninan trendsinutilizationoffirstlinepalliativetreatmentsforanalsquamouscellcarcinoma
AT kazmisyedm trendsinutilizationoffirstlinepalliativetreatmentsforanalsquamouscellcarcinoma